796 related articles for article (PubMed ID: 21199521)
21. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
Mulkay JP; Louis H; Donckier V; Bourgeois N; Adler M; Deviere J; Le Moine O
Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
[TBL] [Abstract][Full Text] [Related]
22. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
23. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
Krag A; Møller S; Henriksen JH; Holstein-Rathlou NH; Larsen FS; Bendtsen F
Hepatology; 2007 Dec; 46(6):1863-71. PubMed ID: 18027874
[TBL] [Abstract][Full Text] [Related]
24. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
Ganne-Carrié N; Hadengue A; Mathurin P; Durand F; Erlinger S; Benhamou JP
Dig Dis Sci; 1996 Jun; 41(6):1054-6. PubMed ID: 8654133
[TBL] [Abstract][Full Text] [Related]
25. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
26. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
27. Terlipressin. Type I hepatorenal syndrome: an extra window of time before liver transplantation.
Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17171813
[TBL] [Abstract][Full Text] [Related]
28. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
29. The management of hepatorenal syndrome.
Carl DE; Sanyal A
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
[TBL] [Abstract][Full Text] [Related]
30. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
Rodríguez E; Elia C; Solà E; Barreto R; Graupera I; Andrealli A; Pereira G; Poca M; Sánchez J; Guevara M; Soriano G; Alessandria C; Fernández J; Arroyo V; Ginès P
J Hepatol; 2014 May; 60(5):955-61. PubMed ID: 24447876
[TBL] [Abstract][Full Text] [Related]
31. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.
Magan AA; Khalil AA; Ahmed MH
World J Gastroenterol; 2010 Nov; 16(41):5139-47. PubMed ID: 21049548
[TBL] [Abstract][Full Text] [Related]
32. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
Piano S; Morando F; Fasolato S; Cavallin M; Boscato N; Boccagni P; Zanus G; Cillo U; Gatta A; Angeli P
J Hepatol; 2011 Aug; 55(2):491-6. PubMed ID: 21334405
[TBL] [Abstract][Full Text] [Related]
33. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
Alessandria C; Debernardi-Venon W; Carello M; Ceretto S; Rizzetto M; Marzano A
Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001
[TBL] [Abstract][Full Text] [Related]
34. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
Halimi C; Bonnard P; Bernard B; Mathurin P; Mofredj A; di Martino V; Demontis R; Henry-Biabaud E; Fievet P; Opolon P; Poynard T; Cadranel JF
Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the management of hepato-renal syndrome (HRS).
Fabrizi F; Martin P; Messa P
Acta Clin Belg; 2007; 62 Suppl 2():393-6. PubMed ID: 18284007
[TBL] [Abstract][Full Text] [Related]
36. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
37. Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation.
Fayed N; Refaat EK; Yassein TE; Alwaraqy M
J Crit Care; 2013 Oct; 28(5):775-82. PubMed ID: 23618777
[TBL] [Abstract][Full Text] [Related]
38. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
39. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
Wang H; Liu A; Bo W; Feng X; Hu Y
Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
[TBL] [Abstract][Full Text] [Related]
40. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
